It looks like the CHMP, Europe's version of the FDA advisory committee, didn't want the month to end without two big positive opinions, giving investors a nice little present heading into the weekend. Celgene's (CELG) relapsed and refractory multiple myeloma drug pomalidomide, and Aegerion's (NASDAQ: AEGR) HoFH drug Juxtapid, are now likely to be approved in the EU.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion and Celgene, along with their competitors.
